Limaye S, Patil D, Akolkar D, Srivastava N, Patil R, Apurwa S, Patil S, John J, Gosavi R, Nesargikar P, Kumar P, Datta V, Bose C, Raazi Z, Srinivasan A, Datar R. Response to pazopanib-based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma.
Clin Case Rep 2021;
9:e04986. [PMID:
34765202 PMCID:
PMC8572349 DOI:
10.1002/ccr3.4986]
[Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 09/30/2021] [Accepted: 10/08/2021] [Indexed: 12/15/2022] Open
Abstract
Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti-cancer agents for treatment of Gastric cancers.
Collapse